21165 ⎘
Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA; Animal cells expressing foreign proteins
T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS
#2BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS
#3PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#4ALTERING GENE EXPRESSION IN CART CELLS AND USES THEREOF
#5ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION
#6METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY
#7INDUCIBLE CASPASES AND METHODS FOR USE
#8ENHANCED ANTIGEN PRESENTING CELL FORMULATIONS
#9BREAST CANCER TUMOR CELL VACCINES
#10ORAL VACCINE COMPOSITION
#11METHODS FOR MASS SPECTROMETRY ANALYSIS OF ENGINEERED CELL COMPOSITIONS
#12COLORECTAL CANCER TUMOR CELL VACCINES
#13ENGINEERED MULTI-COMPONENT SYSTEM FOR IDENTIFICATION AND CHARACTERISATION OF T-CELL RECEPTORS AND T-CELL ANTIGENS
#14ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
#15METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION
#16POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#17ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
#18T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS
#19Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors
#20IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
#21CANCER VACCINES AND METHODS OF USE THEREOF
#22METHODS AND COMPOSITIONS FOR CAR T CELL THERAPY
#23EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS
#24PROTEIN-BASED T-CELL RECEPTOR KNOCKDOWN
#25VACCINE COMPRISING NATURAL KILLER CELLS LOADED WITH LIGANDS OF NATURAL KILLER T CELLS AND CANCER ANTIGENS
#26CHIMERIC ANTIGEN RECEPTORS TARGETING CD70
#27IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
#28CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS
#29TUMOR CELL VACCINES
#30T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS
#31HUMAN CGRP RECEPTOR BINDING PROTEINS
#32PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#33PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#34METHOD FOR TREATING TUMOR USING IMMUNE CELL
#35VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION
#36PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#37HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS
#38CANCER VACCINES TARGETING BORIS AND USES THEREOF
#39IMMUNOTHERAPY TARGETING SOX2 ANTIGENS
#40SHP1 MODIFIED DENDRITIC CELLS AND EXTRACELLULAR VESICLES DERIVED THEREFROM AND ASSOCIATED METHODS
#41ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
#42HLA-G AS A NOVEL TARGET FOR CAR T-CELL IMMUNOTHERAPY
#43BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS
#44COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE
#45CHIMERIC ENGULFMENT RECEPTOR MOLECULES
#46ANTIBODY
#47INHIBITORY CHIMERIC ANTIGEN RECEPTORS
#48MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINASE LIKE 7 (PTK7) AND IMMUNE CELLS EXPRESSING SUCH
#49ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF
#50Methods and Compositions for Cells Expressing a Chimeric Intracellular Signaling Molecule
#51ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF
#52ANTI-HER2 CAR NK CELLS, METHODS OF THEIR PRODUCTION AND USES THEREOF
#53NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME
#54METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY
#55Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens
#56NOVEL CHIMERIC RECEPTOR COMPOSITION, RECOMBINANT VECTOR, CELL, AND APPLICATION THEREOF
#57COMPOSITIONS AND METHODS OF TREATING PLASMA CELL DISORDERS INCLUDING MULTIPLE MYELOMA WITH A VACCINE COMPOSITION AND MYELOMA-SPECIFIC CAR-T CELLS
#58Reducing side effects of immunotherapy using genetically modified hematopoietic cells
#59UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER
#60Altering Gene Expression in CART Cells and Uses Thereof
#61Targeting the Tumor Microenvironment Using Manipulated NKT Cells
#62Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen
#63HETERODIMERIC FC DOMAIN ANTIBODIES
#64TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR
#65PRE-IMMUNIZATION AND IMMUNOTHERAPY
#66CHIMERIC ANTIGEN RECEPTORS AND MODIFIED CELLS COMPRISING THE SAME
#67HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY
#68Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#69mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
#70ARTIFICIAL ADJUVANT VECTOR CELL CAPABLE OF INDUCING IMMUNE RESPONSE TO CORONAVIRUS, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, AND USE APPLICATIONS OF SAID CELL AND SAID PHARMACEUTICAL COMPOSITION
#71BI-SPECIFIC ANTIBODIES FOR USE IN PRODUCING ARMED IMMUNE CELLS
#72BLOCKADE OF CD7 EXPRESSION AND CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES
#73T CELL REGULATION
#74BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF
#75METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF
#76METHODS TO PROTECT TRANSPLANTED TISSUE FROM REJECTION
#77BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#78CANCER VACCINE AND METHOD OF USE THEREOF
#79UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER
#80CHIMERIC ANTIGEN RECEPTOR FUSION PROTEIN CO-EXPRESSING IL-7 AND CCR2B, AND APPLICATION THEREOF
#81CCR4-Targeting Chimeric Antigen Receptor Cell Therapy
#82TUMOR-INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 AND USES THEREOF
#83Compositions and Methods for Treating Cancer with Anti-CD22 Immunotherapy
#84METHODS AND COMPOSITIONS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY
#85CHIMERIC ADAPTOR PROTEINS AND METHODS OF REGULATING GENE EXPRESSION
#86Compositions and methods for immunotherapy
#87Universal influenza vaccine
#88M971 CHIMERIC ANTIGEN RECEPTORS
#89M971 CHIMERIC ANTIGEN RECEPTORS
#90IMMUNOTHERAPY TARGETING TUMOR NEOANTIGENIC PEPTIDES
#91T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS
#92T cell receptor-deficient T cell compositions
#93METHODS AND COMPOSITIONS FOR GENE EDITING IN HEMATOPOIETIC STEM CELLS
#94CHIMERIC ANTIGEN RECEPTORS AND ENHANCEMENT OF ANTI-TUMOR ACTIVITY
#95METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
#96Compositions and Methods for Treating Cancer with DuoCARs
#97Method for generating t-cells compatible for allogenic transplantation
#98COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DUOCARS
#99Hook fusion protein for regulating the cellular trafficking of a target protein
#100BICISTRONIC INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)/ACTIVATING CHIMERIC ANTIGEN RECEPTOR (ACAR) CONSTRUCTS FOR USE IN CANCER THERAPIES
#101CS1 TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS
#102MODIFIED NK-92 CELLS FOR TREATING CANCER
#103GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#104Methods and compositions for modulating CAR-T activity
#105COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS
#106A RATIO BETWEEN PLGF AND SFLT1 IS PREDICTIVE FOR NEURAL INVASION IN PATIENTS SUFFERING FROM PANCREATIC CANCER
#107CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL
#108CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE
#109T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF
#110INDUCIBLE CASPASES AND METHODS FOR USE
#111Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias
#112ANTI-CD83 CAR-T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION
#113HYBRID PROMOTERS, VECTORS CONTAINING SAME AND METHODS OF USE
#114NY-ESO-1-CONTAINING ARTIFICIAL ADJUVANT VECTOR CELL FOR USE IN TREATMENT OF CANCER
#115CHIMERIC ANTIGEN RECEPTORS (CAR) AND METHODS FOR MAKING AND USING THE SAME
#116MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
#117METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
#118CELLULAR VACCINE PLATFORM AND METHODS OF USE
#119CHIMERIC POLYPEPTIDES AND USES THEREOF
#120EDIBLE CELL BASED VACCINES
#121PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#122PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#123PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#124Humanized anti-MUC1* antibodies
#125TECHNIQUE FOR PREPARING UNIVERSAL HUMANISED CAR19-DNT CELLS AND APPLICATION THEREFOR
#126WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF
#127BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
#128METHODS FOR INDUCING SELECTIVE APOPTOSIS
#129COMBINATORIAL CANCER IMMUNOTHERAPY
#130COMPOSITIONS AND METHODS TO TARGET ANTI-RH ANTIBODY
#131Methods, kits, and compositions for enhancing cellular therapy
#132METHODS TO STIMULATE HLA-AGNOSTIC IMMUNE RESPONSES TO PROTEINS USING NUCLEATED CELLS
#133PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#134METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#135Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered form
#136CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND THEIR USE IN CAR-T CELLS
#137PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#138PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#139PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#140PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#141PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#142PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#143PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#144AN IMPROVED MEASLES VIRUS VACCINE VECTOR BASED ON MULTIPLE TANDEM ADDITIONAL TRANSCRIPTION UNITS (ATUS)
#145Binding Members to PD-L1
#146HUMANIZED CD19 ANTIBODY AND USE THEREOF
#147Dendritic cell tumor vaccine and uses thereof
#148PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
#149LIGHT-INDUCIBLE GENE ACTIVATION SYSTEMS AND METHODS FOR MAKING AND USING THEM
#150CELL-MEDIATED SARS-COV-2 VACCINES, AND PREPARATION AND USE THEREOF
#151METHOD FOR DIFFERENTIATING INNATE LYMPHOID CELLS FOR IMMUNOTHERAPY
#152TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
#153REGENERATIVE CAR-T CELLS
#154COMPOSITIONS AND METHODS RELATING TO ANTIVIRAL THERAPEUTICS
#155RAPID VACCINE PLATFORM
#156NOVEL ANTIGEN BINDING DOMAINS AND SYNTHETIC ANTIGEN RECEPTORS INCORPORATING THE SAME
#157TRIFUNCTIONAL T CELL-ANTIGEN COUPLER AND METHODS AND USES THEREOF
#158OVERCOMING THE TUMOR MICROENVIRONMENT FOR CELL THERAPY BY TARGETING MYELOID DERIVED SUPPRESSOR CELLS THROUGH A TRAIL-R2 SPECIFIC RECEPTOR
#159ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
#160METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION
#161METHODS AND COMPOSITIONS RELATING TO CHIMERIC ANTIGEN RECEPTORS
#162METHODS FOR IMMUNOTHERAPY
#163CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND METHODS AND USES THEREOF
#164DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY ASSOCIATED WITH IMMUNODEPLETION
#165Humanized anti-MUC1* antibodies
#166IPSC-BASED VACCINE AS A PROPHYLACTIC AND THERAPEUTIC TREATMENT FOR CANCER
#167ENGINEERED TRIMERIC CD70 PROTEINS AND USES THEREOF
#168TAGGED GENE EDITING TECHNOLOGY FOR CLINICAL CELL SORTING AND ENRICHMENT
#169FLT3-TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS FOR TREATMENT OF FLT3-POSITIVE MALIGNANCIES
#170GPC3 CAR- T CELLS SECRETING IL-18 AND METHODS OF MAKING AND USING THE SAME
#171CHIMERIC ANTIGEN RECEPTORS TARGETING CD33
#172ENGINEERED T CELL RECEPTORS AND METHODS OF USE
#173ALL-IN ONE VECTOR FOR CAR AND THERAPEUTIC EFFECTOR MOLECULE
#174CAR T CELL THERAPIES WITH ENHANCED EFFICACY
#175Engineered immune cell and use thereof
#176CHIMERIC RECEPTORS FOR USE IN ENGINEERED CELLS
#177GENETICALLY ENGINEERED IMMUNE CELLS HAVING A DISRUPTED CD83 GENE
#178ANTIGEN RECEPTORS AND USES THEREOF
#179Immune synapse-stabilizing chimeric antigen receptor (CAR) T cell
#180COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID
#181CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF
#182Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
#183Fractal Combination Therapy
#184ANTI-HPV T CELL RECEPTORS AND ENGINEERED CELLS
#185STROMA-FREE T CELL DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS
#186METHODS FOR DOSING AND TREATMENT OF FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA IN ADOPTIVE CELL THERAPY
#187INTRANASAL mRNA VACCINES
#188CAR for Treatment of HIV Infection
#189MESENCHYMAL STEM CELLS TO ENHANCE ANTI-TUMOR ACTIVITY OF IMMUNOTHERAPY
#190STABILIZED 9 AND 10 SEGMENTED INFLUENZA VIRUSES AS A VACCINE PLATFORM AND METHODS OF MAKING AND USING SAME
#191PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) T CELL RECEPTORS AND METHODS OF USE THEREOF
#192NOVEL DOMINANT NEGATIVE FAS POLYPEPTIDES, CELLS COMPRISING THEREOF AND USES THEREOF
#193CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS
#194PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#195Determining WT-1-Specific T Cells and WT-1 Specific T Cell Receptors (TCRS)
#196Chimeric antigen receptors targeting CD70
#197METHOD FOR PREPARING GENETICALLY-MODIFIED T CELLS WHICH EXPRESS CHIMERIC ANTIGEN RECEPTOR
#198BCMA-binding antibody and use thereof
#199MULTISPECIFIC NANOBODIES CHIMERIC ANTIGEN RECEPTOR AND T-CELL ENGAGER, NUCLEIC ACID, EXPRESSING CELL THEREOF, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, AND METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELL
#200CAR T CELLS WITH ENHANCED METABOLIC FITNESS
#201MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
#202Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
#203NK CELL-BASED THERAPY
#204METASTATIC BRAIN TUMOR TARGETING PEPTIDES
#205Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
#206PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#207METHOD AND COMPOSITIONS FOR REGULATED ARMORING OF CELLS
#208CAR T CELLS THAT TARGET ASPERGILLUS-ASSOCIATED ANTIGENS
#209NY-ESO-1-containing artificial adjuvant vector cell for use in treatment of cancer
#210TUMOR CELL VACCINES
#211Chimeric antigen receptors, compositions and applications thereof
#212Antigen binding molecules specific for an anti-CD19 scFV
#213INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS
#214ANTI-IDIOTYPIC ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
#215Anti-thyroglobulin t cell receptors
#216MODIFIED IMMUNE CELL AND USE THEREOF
#217RENAL CELL CARCINOMA (RCC) THERAPY USING GENETICALLY ENGINEERED T CELLS TARGETING CD70
#218THERAPY FOR HEMATOPOIETIC CELL MALIGNANCIES USING GENETICALLY ENGINEERED T CELLS TARGETING CD70
#219Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
#220PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#221Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
#222PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
#223Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
#224METHOD FOR PRODUCING CYTOTOXIC EFFECTOR MEMORY T-CELLS FOR CAR T-CELL TREATMENT OF CANCER
#225TRIPARTITE SYSTEMS FOR PROTEIN DIMERIZATION AND METHODS OF USE
#226UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER
#227IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY
#228Compositions, methods and kits for eliciting an immune response
#229Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
#230CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
#231DEFINED COMPOSITION GENE MODIFIED T-CELL PRODUCTS
#232Methods and compositions for reducing the immunogenicity of chimeric notch receptors
#233METHODS AND COMPOSITIONS FOR TREATING CANCERS
#234CEREBLON-BASED HETERODIMERIZABLE CHIMERIC ANTIGEN RECEPTORS
#235METHODS FOR ENHANCING EFFICACY OF THERAPEUTIC IMMUNE CELLS
#236METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS
#237Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
#238ROR1 specific chimeric antigen receptors and their therapeutic applications
#239IN SITU RECRUITMENT, REPROGRAMMING, AND RELEASE OF CAR-T CELLS
#240BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS
#241DNMT3A KNOCKOUT CAR T CELLS FOR ADOPTIVE IMMUNOTHERAPY
#242ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME
#243Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
#244COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#245Methods for enhancing efficacy of therapeutic immune cells
#246Chimeric antigen receptors targeting B-cell maturation antigen
#247NOTCH RECEPTORS WITH MINIMAL LINKER
#248T cell receptor-deficient T cell compositions
#249COMBINED EXPRESSION OF A CHIMERIC CD3 FUSION PROTEIN AND AN ANTI-CD3-BASED BISPECIFIC T CELL ACTIVATING ELEMENT
#250Methods and compositions for modulating CAR-T activity
#251COMPOSITIONS AND METHODS FOR TREATING CANCER
#252Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
#253TARGETED CANCER THERAPY
#254Universal influenza vaccine
#255ENGINEERED T CELLS AND USES THEREFOR
#256ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS
#257Anti-podocalyxin antibodies and methods of using the same
#258CAR-T CELL COMPOSITIONS, METHODS OF USE THEREOF
#259GENETICALLY-EDITED IMMUNE CELLS AND METHODS OF THERAPY
#260Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
#261Compositions and Methods for Treating Cancer with DuoCARs
#262Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
#263NK CELL COMPOSITIONS AND PREPARATIONS FOR IMMUNOTHERAPY AND METHODS FOR THEIR PRODUCTION
#264SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER
#265GENETICALLY MODIFIED NK CELLS AND USES THEREOF
#266CELL FREEZING MEDIUM FOR CLINICAL USE
#267COVALENT ADAPTOR SYNNOTCH AND CHIMERIC ANTIGEN RECEPTORS (CARS) FOR PROGRAMMABLE ANTIGEN-TARGETING
#268CELL
#269ANALYTICAL METHOD AND IMMUNOLOGICAL TREATMENT FOR BLADDER CANCER
#270CANCER VACCINE COMPOSITIONS AND METHODS FOR USING SAME TO PREVENT AND/OR TREAT CANCER
#271ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLEY ISOLATED CELLS
#272TREATMENT USING CHIMERIC RECEPTOR T CELLS INCORPORATING OPTIMIZED POLYFUNCTIONAL T CELLS
#273IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS
#274MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
#275IMMUNE CELLS DEFECTIVE FOR SUV39H1
#276ANTI-NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA 1 (NY-ESO-1) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
#277Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
#278COMBINATION THERAPY OF A CELL-MEDIATED CYTOTOXIC THERAPY AND AN INHIBITOR OF A PROSURVIVAL BCL2 FAMILY PROTEIN
#279COMBINATION IMMUNOTHERAPY APPROACH FOR TREATMENT OF CANCER
#280INDUCED ACTIVATION IN DENDRITIC CELLS
#281Methods and compositions for modulating CAR-T activity
#282Coordinating gene expression using RNA destabilizing elements
#283MULTIVALENT CHIMERIC ANTIGEN RECEPTOR
#284ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF
#285CD25-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
#286SIGLEC-BASED CHIMERIC POLYPEPTIDES AND USES THEREOF
#287CELL
#288MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF
#289EXTRACELLULAR VESICLES DERIVED FROM ACTIVATED CAR-T CELLS
#290IMMUNE CELL CONTAINING TUMOR ANTIGEN RECOGNITION RECEPTOR AND APPLICATION THEREOF
#291CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELL
#292HYPOXIA-RESPONSIVE CHIMERIC ANTIGEN RECEPTORS
#293CHIMERIC ANTIGEN RECEPTORS WITH CD20 SAFETY SWITCH
#294OVEREXPRESSION OF IMMUNOPROTEASOME IN HOST CELLS FOR GENERATING ANTIGEN-PRESENTING CELLS
#295HETERO-STRUCTURED RIBONUCLEIC ACID AND USE THEREOF
#296GENETICALLY REPROGRAMMED TREGS EXPRESSING CARS
#297Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins
#298Chimeric antigen receptors (CARS) that bind osteosarcoma and their use in medicine
#299Compositions and Methods for Treating Cancer with DuoCARs
#300T CELL RECEPTORS AND METHODS OF USE THEREOF